Tohoku University Venture Partners, JIC Venture Growth Investments, Astellas Venture Management LLC, and eight other companies, as well as an AMED grant, raised a total of approximately 1.5 billion yen in Series B round funding.

Toregem has raised a total of approximately JPY 1.5 billion in funding through a third-party allotment of new shares (Series B) and a grant from the 2024 “Drug Discovery Venture Ecosystem Enhancement Project (Drug Discovery Venture Open Call)” (4th round) of the National Institute for Medical Research and Development (AMED).

With this funding, the company will conduct Phase I clinical trials of TRG035 (humanised anti-USAG-1 antibody) and prepare for Phase II clinical trials to further accelerate the clinical development of the world's first tooth regeneration treatment.